Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort
Journal of Neuro-Oncology · 2026-05 · 178 (1)
DOI: 10.1007/s11060-026-05658-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 29.05.2026. Verfasst von Clemente García-Hidalgo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiology Department, Hospital Morales Meseguer, Murcia, Spain. clemente292@gmail.com. Hauptthemen laut MEDLINE: CD79 Antigens, Biomarkers, Tumor, Magnetic Resonance Imaging, Central Nervous System Neoplasms. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To test, under a pre-planned clinical framework, whether simple multiparametric MRI biomarkers show candidate associations with selected molecular alterations in primary central nervous system lymphoma (PCNSL), with a focus on non-invasive enrichment for CD79B status and the MCD-like phenotype of potential relevance to Bruton tyrosine kinase (BTK) inhibitor stratification. METHODS: The public UCSF-PCNSL dataset (146 patients; 63 with UCSF500 cancer gene panel) was analyzed. Four clinically motivated MRI biomarker-to-genotype pairings (CD79B, MCD-like, TP53, and CDKN2A/B) were defined in advance of any statistical testing. Effect sizes were reported as Cliff's delta with 95% bootstrap confidence intervals, and one-sided p-values were adjusted for multiple testing across the four hypotheses at a false-positive threshold of 0.05. Reproducibility was examined by refitting each test after removing one scanner batch at a time (six batches total), and by benchmarking the habitat biomarkers against simple volumetric predictors using cross-validated AUROC. RESULTS: The principal hypothesis (H1) showed a higher enhancing-core (h1) fraction in CD79B-mutant patients (Cliff's delta + 0.34, 95% CI + 0.04 to + 0.63; rank AUC 0.67; p = 0.015; direction preserved in 6/6 scanner batches). H3 was directionally consistent: higher FLAIR/T1c ratio in TP53-mutant patients (delta + 0.31; p = 0.049). MCD-like and CDKN2A/B hypotheses were not supported. After correction for multiple testing, no test reached the 0.05 threshold. CONCLUSION: In this exploratory analysis, enhancing-core fraction on routine MRI emerged as the leading candidate signal for CD79B status in PCNSL, with FLAIR/T1c ratio as a directionally consistent secondary signal for TP53. After correction for multiple testing across the four pre-specified comparisons no test reached the 0.05 threshold; the findings should therefore be considered hypothesis-generating. External multicenter replication, ideally with full LymphGen classification, is required before these biomarkers can be considered for clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiology Department, Hospital Morales Meseguer, Murcia, Spain. clemente292@gmail.com.
- Radiology Department, Hospital 12 de Octubre, Madrid, Spain.
- Neurology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
- Radiology Department, Hospital Morales Meseguer, Murcia, Spain.
Zitieren
APA
García-Hidalgo, C., García Kempf, A. M., Galdo Galián, D., Consentino Hernández, J. A., & Cayuela Espí, J. V. (2026). Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. Journal of Neuro-Oncology, 178(1). https://doi.org/10.1007/s11060-026-05658-5
Vancouver
García-Hidalgo C, García Kempf AM, Galdo Galián D, Consentino Hernández JA, Cayuela Espí JV. Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. Journal of Neuro-Oncology. 2026;178(1). doi:10.1007/s11060-026-05658-5
BibTeX
@article{GarcaHidalgo2026,
author = {García-Hidalgo, Clemente and García Kempf, Audena María and Galdo Galián, David and Consentino Hernández, José Antonio and Cayuela Espí, José Vicente},
title = {Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort},
journal = {Journal of Neuro-Oncology},
year = {2026},
volume = {178},
number = {1},
doi = {10.1007/s11060-026-05658-5}
}
EUVIMED